Authors
Barsukov A.V.1, Gulyaev A.V1., Mitrofanova L.B2., Shishkevich A.N.1, Saifullin R.F.1, Iakovlev V.V.1, Iakovlev V.A.1
1. S.M. Kirov Military Medical Academy.
2. National Almazov Medical Research Centre, St. Petersburg.
Abstract
The intravenous inodilator Levosimendan was originally developed for intensive therapy of acute decompensated heart failure. In recent years, there has been a definite scientific and clinical interest in its repeated or planned periodic use in patients with severe chronic heart failure (CHF). Data were obtained on the beneficial long-term effects of levosimendan with regular administration to hemodynamic parameters, neurohormonal markers, mediators of systemic inflammation and, most importantly, clinical outcomes in patients with contractile myocardial dysfunction of different genesis. This paper presents a clinical case of levosimendan use in the complex treatment of a 50-year-old patient with decompensated CHF caused by dilated post-inflammatory cardiomyopathy.
Keywords: chronic heart failure, levosimendan, dilated post-inflammatory cardiomyopathy.
References
1. Ageev, F.T. Bol'nye s hronicheskoj serdechnoj nedostatochnost'yu v rossijskoj ambulatornoj praktike: osobennosti kontingenta, diagnostiki i lecheniya (po materialam issledovaniya EHPOHA–O–HSN) / F.T.Ageev, M.O.Danielyan, V.YU. Mareev // Serdechnaya nedostatochnost'. – 2004. – № 5 (1). – S. 4-7.
2. Ageev, F.T. Rasprostranennost' hronicheskoj serdechnoj nedostatochnosti v Evropejskoj chasti Rossijskoj Federacii – dannye EHPOHA–HSN / F.T. Ageev, I.V. Fomin, YU.N.Belenkov // Serdechnaya nedostatochnost'. – 2006. – № 7 (1). – S. 112-115.
3. Badin, YU.V. Vyzhivaemost' bol'nyh HSN v kogortnoj vyborke Nizhegorodskoj oblasti (dannye 1998 – 2002 godov.) /YU.V. Badin, I.V.Fomin //Mat. Vseross.Konf.”OSSN: Serdechnayanedostatochnost'”. – 2005. –S. 31-32.
4. Barsukov, A.V. Ostryj virusnyj miokardit: ot diagnoza k lecheniyu /A.V. Barsukov, D.V. Gluhovskoj // Klinicheskaya patofiziologiya. – 2017. – № 2. – S. 41-50.
5. Belenkov, YU.N. Pervye rezul'taty Rossijskogo ehpidemiologicheskogo issledovaniya po HSN / YU.N. Belenkov// Serdechnaya nedostatochnost'. – 2003. – № 4 (1). – S. 26-30.
6. Belousov YU.B. Farmakoehkonomicheskij analiz primeneniya levosimendana u bol'nyh s tyazheloj dekompensirovannoj hronicheskoj serdechnoj nedostatochnost'yu/ YU.B. Belousov, D.YU. Belousov, V.YU. Grigor'ev //Serdechnaya nedostatochnost'. – 2006. – №1. – S. 32-38.
7. Danielyan, M.O. Prognoz i lechenie hronicheskoj serdechnoj nedostatochnosti (dannye 20-i letnego nablyudeniya): avtoref. dis… kand. med. nauk /M.O. Danielyan. – M., 2001. – 24 s.
8. Mareev, V.YU. Klinicheskie rekomendacii. Hronicheskaya serdechnaya nedostatochnost' (HSN) /V.YU. Mareev, I.V. Fomin, F.T.Ageev // Serdechnayanedostatochnost'. – 2017. –№. 1. – S. 3-40.
9. Moiseev, V.S. Bezopasnost' i ehffektivnost' levosimendana u bol'nyh levozheludochkovoj nedostatochnost'yu pri ostrom infarkte miokarda. Randomizirovannoe dvojnoe slepoe placebo-kontroliruemoe issledovanie (RUSSLAN) / V.S. Moiseev, P. Poder, N.A. Andreev //Klin. Farmakol. Ter. – 2004. – T.13, №4. – S. 32-38.
10. Nieminen, M.S. Levosimendan: klinicheskie dannye, prakticheskoe primenenie i perspektivy/M.S.Nieminen, S.Fruhwald, L.M.A.Heunks//Atmosfera. Novosti kardiologii. – 2014. – № 3. –S. 30-44.
11. Simdaks®. Monografiya po preparatu.- Orion Farma, 2015. – 94 s.
12. YAvelov I.S. Levosimendan ne prevoskhodit dobutamin po vliyaniyu na smertnost' pri ostroj serdechnoj nedostatochnosti: rezul'taty issledovaniya SURVIVE /I.S. YAvelov // Kardiologiya. – 2007. – №47. – S. 71-72.
13. YAvelov I.S. Novoe kardiotonicheskoe lekarstvennoe sredstvo levosimendan: osobennosti prakticheskogo ispol'zovaniya / I.S.YAvelov // Serdechnaya nedostatochnost'. – 2005. – № 1. – S. 1-16.
14. Cleland, J.G. TheEuroHeartFailuresurveyprogrammeasurveyonthequalityofcareamongpatientswithheartfailureinEurope. Part 1: patient characteristics and diagnosis / J.G. Cleland // Eur. Heart J. – 2003. – Vol. 5, № 24. – P. 442-463.
15. De Lissovoy, G. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial / G. De Lissovoy, K.Fraeman, J. Salon // J. Med. Econ. – 2008. – Vol. 11 (3). – P. 415-429.
16. De Lissovoy, G. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study / G. De Lissovoy., K.Fraeman, J.R.Teerlink// Eur. J. Health Econ. – 2010. –Vol. 11, № 2. –P. 185-193.
17. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016 / P. Ponikowski, A.A. Voors, S.D. Anker// Eur. Heart J. – 2016. – Vol. 37, № 27 – P. 2129-2200.
18. Fedele, F. Cost-effectiveness of levosimendan in patients with acute heart failure/F. Fedele, A.D’Ambrosi, N.Bruno //J. Cardiovasc. Pharmacol. – 2011. – Vol. 58 (4). – P. 363-366.
19. Haikala, H. Calcium sensitivity enhancers / H.Haikala,P. Pollesello // IDrugs – 2000. – Vol. 3.– P. 1199-1205.
20. Landoni, G. Effects of levosimendan on mortality and hospitalization. A metaanalysis of randomized controlled studies / G.Landoni, G.Biondi-Zoccai, M. Greco //Crit. Care Med. – 2012. – Vol. 40 (2). – P. 634-646.
21. Lilleberg, J. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure / J.Lilleberg, M.Laine, T.Palkama// Eur. J. HeartFail. –2007.–Vol. 9 (1).– P. 75-82.
22. Mebazaa, A. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial / A.Mebazaa, M.S.Nieminen, M.Packer // JAMA. – 2007. – Vol. 297 (17). – P. 1883-1891.
23. Nainggolan L. CASINO results: Should docs gamble on levosimendan? –2004.//www.medscape.com/viewarticle/784798.
24. Nieminen, M.S., Levosimendan: current data, clinical use and future development / M.S. Nieminen, S. Fruhwald, L.M.A. Heunk// Heart, Lung and Vessels. – 2013. – Vol. 5. – Р. 227-245.
25. Papp, Z.Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan / Z. Papp, I. Édes, S. Fruhwald // Int. J. Cardiol. – 2012. – Vol. 159. –Р. 82-87.
26. Peck, P. Levosimendan shows significant survival benefit in decompensated heart ailure.// www.cardiology.medscape.com /viewarticle/471463/10.03.2004.
27. Szilágyi, S. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone / S. Szilágyi, P. Pollesello,J. Levijoki // J. Cardiovasc.Pharmacol. – 2005. – Vol. 46. – Р.369-376.
